Repligen price target raised to $225 from $175 at Craig-Hallum

Craig-Hallum raised the firm’s price target on Repligen to $225 from $175 and keeps a Buy rating on the shares. Repligen reproted in line Q4 results and initial FY24 guidance reflects slower than anticipated growth, the analyst tells investors in a research note. The firm believes the company has seen a bottom and will slowly make its way back to its historical growth levels.